Vol.:(0123456789) Vol.:(0123456789) vol.:(0123456789) V Vo Vol Vol. BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 0 .:() 4 10 0 1 0 0 0
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ()():- 6 10 0 1 1 1 1
https://doi.org/10.1007/s13555-024-01207-y https://doi.org/10.1007/s13555-024-01207-y https://doi.org/10.1007/s13555-024-01207-y h ht htt http BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 0 0 ://././--- 10 9 0 1 0 0 1
ORIGINAL RESEARCH original O OR ORI ORIG BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 1 0 0 1
Ustekinumab in ustekinumab U Us Ust Uste BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 : 1 10 0 0 0 0 1
A Systematic a A A A A BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 0 0 - 1 9 0 0 0 0 1
Rahul Masson rahul R Ra Rah Rahu BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ••••• 5 10 0 0 0 0 1
Marcia Hogeling marcia M Ma Mar Marc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 1 •.•. 4 10 0 0 0 0 1
Received: April received: R Re Rec Rece BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 :,/:,/:, 8 10 0 0 0 0 1
© The © © © © © BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 1 () 2 2 0 0 0 0 1
ABSTRACT ABSTRACT abstract A AB ABS ABST BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 10 0 0 0 0 1
Introduction: Hidradenitis introduction: I In Int Intr BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 :() 3 8 0 0 0 0 1
is a is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 , 1 9 0 0 0 0 1
condition. Patients condition. c co con cond BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 9 0 0 0 0 1
to adalimumab, to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 , 1 8 0 0 0 0 1
Drug Administration drug D Dr Dru Drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 ()- 3 8 0 0 0 0 1
treatment for treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 .- 2 8 0 0 0 0 1
kin-12/23 inhibitor kin-12/23 k ki kin kin- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 2 -/ 2 9 0 0 0 0 1
HS, but hs, H HS HS, HS, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 ,- 2 8 0 0 0 0 1
atic review atic a at ati atic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 . 1 10 0 0 0 0 1
this study this t th thi this BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 9 0 0 0 0 1
meta-analysis of meta-analysis m me met meta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 - 1 9 0 0 0 0 1
and safety and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 6 0 0 0 0 1
Methods: In methods: M Me Met Meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 :, 2 7 0 0 0 0 1
Embase databases embase E Em Emb Emba BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
on ustekinumab on o on on on BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 8 0 0 0 0 1
performed on performed p pe per perf BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 - 1 8 0 0 0 0 1
ers. The ers. e er ers ers. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 . 1 9 0 0 0 0 1
response rate response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 .- 2 8 0 0 0 0 1
effects meta-analysis effects e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 -, 2 8 0 0 0 0 1
Cochran's Q cochran's C Co Coc Coch BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 4 ' 1 9 0 0 0 0 1
used to used u us use used BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 .- 2 9 0 0 0 0 1
cance was cance c ca can canc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 .. 2 9 0 0 0 0 1
is based is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 8 0 0 0 0 1
does not does d do doe does BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 8 0 0 0 0 1
participants or participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 9 0 0 0 0 1
authors. authors. authors. a au aut auth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 . 1 1 0 0 0 0 1
Results: From results: R Re Res Resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 4 :,( 3 9 0 0 0 0 1
case series case c ca cas case BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 4 ) 1 9 0 0 0 0 1
patients met patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 . 1 10 0 0 0 0 1
reported disease reported r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 9 0 0 0 0 1
(17.6%, 12/68) (17.6%, ( (1 (17 (17. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 4 (.,/)(.,/). 11 9 0 0 0 0 1
majority (80.7%, majority m ma maj majo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 (.,/) 5 9 0 0 0 0 1
least one least l le lea leas BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 .- 2 9 0 0 0 0 1
R. Masson r. R R. R. R. BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 . 1 2 0 0 0 0 1
Keck School keck K Ke Kec Keck BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 8 , 1 9 0 0 0 0 1
of Southern of o of of of BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 8 ,,, 3 10 0 0 0 0 1
J. Seivright j. J J. J. J. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 . 1 3 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 8 , 1 10 0 0 0 0 1
Permanente Los permanente P Pe Per Perm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 , 1 9 0 0 0 0 1
Los Angeles, los L Lo Los Los BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 ,, 2 5 0 0 0 0 1
T. Grogan t. T T. T. T. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 . 1 1 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 , 1 8 0 0 0 0 1
Geffen School geffen G Ge Gef Geff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 ,, 2 10 0 0 0 0 1
Los Angeles, los L Lo Los Los BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 ,, 2 3 0 0 0 0 1
S. Atluri s. S S. S. S. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 . 1 1 0 1 0 0 1
University of university U Un Uni Univ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 ,, 2 10 0 1 0 0 1
AZ, USA az, A AZ AZ, AZ, BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 , 1 1 0 1 0 0 1
I. Hamzavi i. I I. I. I. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 . 1 2 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 ,, 2 10 0 0 0 0 1
Detroit, MI, detroit, D De Det Detr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 ,, 2 3 0 0 0 0 1
M. Hogeling m. M M. M. M. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 . 1 2 0 0 0 0 1
Division of division D Di Div Divi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 , 1 10 0 0 0 0 1
Los Angeles, los L Lo Los Los BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 ,,, 3 6 0 0 0 0 1
V. Y. v. V V. V. V. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 .. 2 2 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 , 1 10 0 0 0 0 1
for Medical for f fo for for BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 ,,, 3 8 0 0 0 0 1
J. L. j. J J. J. J. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 11 ..(*) 5 3 0 1 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 11 , 1 9 0 1 0 0 1
California, 1441 california, C Ca Cal Cali BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 11 ,,, 3 10 0 1 0 0 1
5301, Los 5301, 5 53 530 5301 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 11 ,,-, 4 7 0 1 0 0 1
e-mail: j.hsiao.publications@gmail.com e-mail: e e- e-m e-ma BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 11 -:..@. 6 7 0 1 0 0 1
1902 1902 1902 1 19 190 1902 BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 0 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ()():- 6 10 0 1 1 0 1
all ten all a al all all BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 9 0 0 0 0 1
of 67% of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 (.-.). 6 8 0 0 0 0 1
include a include i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 - 1 8 0 0 0 0 1
omized controlled omized o om omi omiz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 (). 3 6 0 0 0 0 1
Conclusions: Ustekinumab conclusions: C Co Con Conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 :- 2 7 0 0 0 0 1
ful treatment ful f fu ful ful BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 9 0 0 0 0 1
recalcitrant to recalcitrant r re rec reca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 -, 2 10 0 0 0 0 1
RCTs are rcts R RC RCT RCTs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 8 0 0 0 0 1
regimens and regimens r re reg regi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 9 0 0 0 0 1
that would that t th tha that BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 . 1 8 0 0 0 0 1
Keywords: Biologic keywords: K Ke Key Keyw BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 :;; 3 9 0 0 0 0 1
Hidradenitis suppurativa; hidradenitis H Hi Hid Hidr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 1 ;; 2 10 0 0 0 0 1
Meta-analysis Meta-analysis meta-analysis M Me Met Meta BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 1 - 1 3 0 0 0 0 1
Key Summary key K Ke Key Key BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 1 no 0 10 0 0 0 0 1
Although ustekinumab although A Al Alt Alth BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
hidradenitis suppurativa hidradenitis h hi hid hidr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 (), 3 10 0 0 0 0 1
of comprehensive of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 9 0 0 0 0 1
and efficacy. and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 2 0 0 0 0 1
In this in I In In In BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 2 - 1 9 0 0 0 0 1
of ten of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 , 1 10 0 0 0 0 1
the pooled the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 9 0 0 0 0 1
67%. The 67%. 6 67 67% 67%. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 2 . 1 9 0 0 0 0 1
failed treatment failed f fa fai fail BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
agents. agents. agents. a ag age agen BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 1 0 0 0 0 1
Our study our O Ou Our Our BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 no 0 10 0 0 0 0 1
of ustekinumab of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 no 0 9 0 0 0 0 1
treatment option treatment t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 . 1 5 0 0 0 0 1
INTRODUCTION INTRODUCTION introduction I IN INT INTR BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 no 0 10 0 0 0 0 1
Hidradenitis suppurativa hidradenitis H Hi Hid Hidr BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 3 (), 3 8 0 0 0 0 1
oftentimes debilitating oftentimes o of oft ofte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 - 1 9 0 0 0 0 1
sents with sents s se sen sent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 ,,, 3 9 0 0 0 0 1
scarring, typically scarring, s sc sca scar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 ,[]. 4 9 0 0 0 0 1
The pathogenesis the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 - 1 8 0 0 0 0 1
passes genetic passes p pa pas pass BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 [],[],- 7 9 0 0 0 0 1
cal, hormonal, cal, c ca cal cal, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 ,,[]. 5 9 0 0 0 0 1
Though many though T Th Tho Thou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 - 1 8 0 0 0 0 1
pies are pies p pi pie pies BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 , 1 10 0 0 0 0 1
is often is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 []. 3 9 0 0 0 0 1
recent advances recent r re rec rece BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 , 1 9 0 0 0 0 1
substantial unmet substantial s su sub subs BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 10 0 0 0 0 1
solutions [6]. solutions s so sol solu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 [].,- 5 9 0 0 0 0 1
tor (TNF)-alpha tor t to tor tor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 5 ()-,, 5 9 0 0 0 0 1
interleukin (IL)-17 interleukin i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 5 ()-, 4 10 0 0 0 0 1
only FDA-approved only o on onl only BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 -- 2 9 0 0 0 0 1
ment of ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 5 ., 2 8 0 0 0 0 1
have an have h ha hav have BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 - 1 8 0 0 0 0 1
alpha or alpha a al alp alph BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 5 -[]. 4 10 0 0 0 0 1
IL-12 and il-12 I IL IL- IL-1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 5 -- 2 10 0 0 0 0 1
in patients in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 5 , 1 9 0 0 0 0 1
data on data d da dat data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 10 0 0 0 0 1
[8]. The [8]. [ [8 [8] [8]. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 5 []. 3 9 0 0 0 0 1
evaluate existing evaluate e ev eva eval BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 10 0 0 0 0 1
safety of safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 - 1 9 0 0 0 0 1
duct a duct d du duc duct BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 -. 2 9 0 0 0 0 1
useful for useful u us use usef BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 9 0 0 0 0 1
with HS, with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 ,- 2 8 0 0 0 0 1
quate responses quate q qu qua quat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 5 , 1 10 0 0 0 0 1
regarding treatment regarding r re reg rega BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 . 1 7 0 0 0 0 1
METHODS METHODS methods M ME MET METH BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 no 0 10 0 0 0 0 1
Search Strategy search S Se Sea Sear BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 no 0 10 0 0 0 0 1
This study this T Th Thi This BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 - 1 7 0 0 0 0 1
ferred Reporting ferred f fe fer ferr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 no 0 9 0 0 0 0 1
and Meta-Analyses and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 -() 3 7 0 0 0 0 1
(Fig. 1) (fig. ( (F (Fi (Fig BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 (.) 3 8 0 0 0 0 1
(CRD42022364634). On (crd42022364634). ( (C (CR (CRD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 1 8 ()., 4 8 0 0 0 0 1
independent reviewers independent i in ind inde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 (....) 6 9 0 0 0 0 1
MEDLINE and medline M ME MED MEDL BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 - 1 8 0 0 0 0 1
tion to tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 : 1 9 0 0 0 0 1
("hidradenitis suppurativa" ("hidradenitis ( (" ("h ("hi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 ("""- 5 8 0 0 0 0 1
tis" OR tis" t ti tis tis" BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 """"" 5 8 0 0 0 0 1
OR "verneuil or O OR OR OR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 "")(""). 8 8 0 0 0 0 1
A total a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 1 8 . 1 10 0 0 0 0 1
were filtered were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 -- 2 9 0 0 0 0 1
and nonhuman and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 . 1 9 0 0 0 0 1
excluded, and excluded, e ex exc excl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 , 1 9 0 0 0 0 1
remaining articles remaining r re rem rema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 . 1 9 0 0 0 0 1
Full-text review full-text F Fu Ful Full BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 - 1 8 0 0 0 0 1
remaining 112 remaining r re rem rema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 no 0 9 0 0 0 0 1
reviewers (R.M. reviewers r re rev revi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 (....). 7 10 0 0 0 0 1
ustekinumab as ustekinumab u us ust uste BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 no 0 8 0 0 0 0 1
HS, contained hs, H HS HS, HS, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 ,, 2 9 0 0 0 0 1
three or three t th thr thre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 no 0 9 0 0 0 0 1
for inclusion. for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 .,, 3 9 0 0 0 0 1
meta-analyses, commentaries, meta-analyses, m me met meta BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 -,, 3 9 0 0 0 0 1
1903 1903 1903 1 19 190 1903 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 1 0 no 0 1 1 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 ()():- 6 10 1 1 1 0 1
Fig. 1 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 ..,,- 5 9 1 0 0 0 1
ziaff J, ziaff z zi zia ziaf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 1 ,,() 4 10 1 0 0 0 1
reporting items reporting r re rep repo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 1 -- 2 10 1 0 0 0 1
ses: the ses: s se ses ses: BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 6 :.():. 6 8 1 0 0 0 1
https:// doi. https:// h ht htt http BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 1 1 6 ://././.. 9 10 1 0 0 0 1
information, visit information, i in inf info BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 ,.-. 4 7 1 0 0 0 1
1904 1904 1904 1 19 190 1904 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 1 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 ()():- 6 10 0 1 1 0 1
articles were articles a ar art arti BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 9 0 0 0 0 1
discussed to discussed d di dis disc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
(J.L.H.). Reference (j.l.h.). ( (J (J. (J.L BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 (...). 6 10 0 0 0 0 1
inclusion criteria inclusion i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
relevant articles, relevant r re rel rele BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,. 2 8 0 0 0 0 1
This article this T Th Thi This BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
studies and studies s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
with human with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
by any by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 9 0 0 0 0 1
study are study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 :::// 5 9 0 0 0 0 1
pubmed. ncbi. pubmed. p pu pub pubm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 ..../::// 9 9 0 0 0 0 1
www. embase. www. w ww www www. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 ..//. 5 6 0 0 0 0 1
Data Extraction data D Da Dat Data BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 10 0 0 0 0 1
Two reviewers two T Tw Two Two BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 (....) 6 8 0 0 0 0 1
completed data completed c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 . 1 8 0 0 0 0 1
reviewed, and reviewed, r re rev revi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 , 1 8 0 0 0 0 1
collected: study collected: c co col coll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 :,, 3 10 0 0 0 0 1
characteristics, HS characteristics, c ch cha char BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 ,, 2 9 0 0 0 0 1
affected by affected a af aff affe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 ,, 2 9 0 0 0 0 1
concomitant treatments, concomitant c co con conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 ,- 2 8 0 0 0 0 1
bidities, study bidities, b bi bid bidi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 ,,- 3 9 0 0 0 0 1
ment/timepoint of ment/timepoint m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 /,- 3 9 0 0 0 0 1
ment response, ment m me men ment BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 ,. 2 7 0 0 0 0 1
Meta-analysis Meta-analysis meta-analysis M Me Met Meta BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 - 1 10 1 0 0 0 1
A meta-analysis a A A A A BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 2 5 - 1 10 1 0 0 0 1
pooled estimated pooled p po poo pool BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 - 1 10 1 0 0 0 1
numab. To numab. n nu num numa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 ., 2 9 1 0 0 0 1
primary clinician primary p pr pri prim BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 no 0 9 1 0 0 0 1
were used were w we wer were BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ,- 2 8 0 0 0 0 1
sician assessments; sician s si sic sici BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 ; 1 8 0 0 0 0 1
(HiSCR) was (hiscr) ( (H (Hi (HiS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 () 2 9 0 0 0 0 1
reported outcome reported r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 .- 2 8 0 0 0 0 1
est plots est e es est est BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 no 0 9 0 0 0 0 1
of patients of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ( 1 9 0 0 0 0 1
partial response) partial p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ), 2 9 0 0 0 0 1
errors/confidence intervals errors/confidence e er err erro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 / 1 9 0 0 0 0 1
inverse variance inverse i in inv inve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 (.).' 5 9 0 0 0 0 1
Q statistic q Q Q Q Q BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 2 5 ( 1 9 0 0 0 0 1
of variation of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 - 1 9 0 0 0 0 1
geneity rather geneity g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 ) 1 9 0 0 0 0 1
heterogeneity. Because heterogeneity. h he het hete BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 . 1 9 0 0 0 0 1
was not was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ,--- 4 9 0 0 0 0 1
cal model cal c ca cal cal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 2 5 - 1 8 0 0 0 0 1
effects pooled effects e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 . 1 9 0 0 0 0 1
performed using performed p pe per perf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ..(.-. 6 9 0 0 0 0 1
org). p-Values org). o or org org) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 ).-. 4 10 0 0 0 0 1
significant. significant. significant. s si sig sign BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 . 1 2 0 0 0 0 1
RESULTS RESULTS results R RE RES RESU BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 1 1 0 0 0 0 0 2 9 no 0 10 0 0 0 0 1
Ten articles ten T Te Ten Ten BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 9 1 0 0 0 1
met inclusion met m me met met BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 . 1 9 1 0 0 0 1
across nine across a ac acr acro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 9 1 0 0 0 1
trial. Study trial. t tr tri tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 .(), 4 9 1 0 0 0 1
USA (n usa U US USA USA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 9 (),(), 6 9 1 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 9 (),(),(). 9 9 1 0 0 0 1
Study characteristics, study S St Stu Stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 ,, 2 10 1 0 0 0 1
treatment regimens, treatment t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 ,, 2 8 1 0 0 0 1
Fig. 2 fig. F Fi Fig Fig. BLOCKSTART PAGEEND NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 11 .- 2 10 1 1 0 0 1
1905 1905 1905 1 19 190 1905 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 2 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 ()():- 6 10 0 1 1 0 1
Table 1 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 1 0 0 0 0 1
Hidradenitis suppurativa hidradenitis H Hi Hid Hidr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 no 0 10 0 0 0 0 1
Study reference study S St Stu Stud BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 10 0 0 0 0 1
Dosing Dosing dosing D Do Dos Dosi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 1 0 0 0 0 1
Patients characteristics patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 (,, 3 9 0 0 0 0 1
affected areas, affected a af aff affe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 ,- 2 8 0 0 0 0 1
bidities, previously bidities, b bi bid bidi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ,, 2 10 0 0 0 0 1
concomitant treatments) concomitant c co con conc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ) 1 6 0 0 0 0 1
Treatment response treatment T Tr Tre Trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 10 0 0 0 0 1
effects effects effects e ef eff effe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 10 0 0 0 0 1
Timepoint(s) of timepoint(s) T Ti Tim Time BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 1 () 2 10 0 0 0 0 1
measurement measurement measurement m me mea meas BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 4 0 0 0 0 1
Blok et blok B Bl Blo Blok BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 1 .[];- 5 10 0 0 0 0 1
erlands; prospective erlands; e er erl erla BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 1 ; 1 9 0 0 0 0 1
45 mg 45 4 45 45 45 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 2 2 no 0 2 0 0 0 0 1
(90 mg (90 ( (9 (90 (90 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 2 ( 1 3 0 0 0 0 1
pts > pts p pt pts pts BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 ), 2 5 0 0 0 0 1
4, 16, 4, 4 4, 4, 4, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 2 ,, 2 2 0 0 0 0 1
n = n n n n n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 2 2 (,),( 5 10 0 0 0 0 1
20-53) 20-53) 20-53) 2 20 20- 20-5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 3 -) 2 1 0 0 0 0 1
Comorbidities: obesity comorbidities: C Co Com Como BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 3 :();, 5 10 0 0 0 0 1
acne conglobata acne a ac acn acne BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 ();(); 6 10 0 0 0 0 1
hypothyroidism, diabetes, hypothyroidism, h hy hyp hypo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 3 ,,- 3 8 0 0 0 0 1
lipidemia, hypercholesterolemia, lipidemia, l li lip lipi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 3 ,, 2 10 0 0 0 0 1
(n = (n ( (n (n (n BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 () 2 1 0 0 0 0 1
PFT: abx pft: P PF PFT PFT: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 :(); 4 8 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 ();(); 6 7 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 ();();, 7 8 0 0 0 0 1
excision (n excision e ex exc exci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 ();(); 6 10 0 0 0 0 1
IFX (n ifx I IF IFX IFX BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 ();,- 5 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 ();() 5 6 0 0 0 0 1
CT: topical ct: C CT CT: CT: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 :(); 4 8 0 0 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 ();() 5 4 0 0 0 0 1
40 w 40 4 40 40 40 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 2 6 no 0 2 0 0 0 0 1
HiSCR: 47.1% hiscr: H Hi HiS HiSC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 6 :.(/) 5 10 0 0 0 0 1
mSS: 112.1 mss: m mS mSS mSS: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 :. 2 6 0 0 0 0 1
60.2 (p 60.2 6 60 60. 60.2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 6 .(.) 4 8 0 0 0 0 1
Marked improvement: marked M Ma Mar Mark BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 :.(/) 5 10 0 0 0 0 1
Moderate improvement: moderate M Mo Mod Mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 :. 2 8 0 0 0 0 1
(8/17) (8/17) (8/17) ( (8 (8/ (8/1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 7 (/) 3 2 0 0 0 0 1
Mild improvement: mild M Mi Mil Mild BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 :.(/) 5 9 0 0 0 0 1
No change no N No No No BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 :. 2 9 0 0 0 0 1
(2/17) (2/17) (2/17) ( (2 (2/ (2/1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 7 (/) 3 2 0 0 0 0 1
mHSLASI: 26.3 mhslasi: m mH mHS mHSL BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 :. 2 4 0 0 0 0 1
19.6 (p 19.6 1 19 19. 19.6 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 7 .(.) 4 4 0 0 0 0 1
Marked improvement: marked M Ma Mar Mark BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 8 :.(/) 5 10 0 0 0 0 1
Moderate improvement: moderate M Mo Mod Mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 8 :. 2 8 0 0 0 0 1
(6/17) (6/17) (6/17) ( (6 (6/ (6/1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 8 (/) 3 2 0 0 0 0 1
Mild improvement: mild M Mi Mil Mild BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 8 :.(/) 5 9 0 0 0 0 1
No change no N No No No BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 8 :. 2 9 0 0 0 0 1
(5/17) (5/17) (5/17) ( (5 (5/ (5/1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 8 (/) 3 2 0 0 0 0 1
DLQI: 41.2% dlqi: D DL DLQ DLQI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 8 :.(/) 5 5 0 0 0 0 1
VAS pain: vas V VA VAS VAS BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 8 :. 2 4 0 0 0 0 1
4.6 4.6 4.6 4 4. 4.6 4.6 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 10 . 1 10 0 0 0 0 1
Skindex-29: 35.3% skindex-29: S Sk Ski Skin BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 10 -:.(/) 6 10 0 0 0 0 1
17.6% (3/17) 17.6% 1 17 17. 17.6 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 10 .(/)/ 5 8 0 0 0 0 1
response, 5.9% response, r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 ,.(/)/ 6 10 0 0 0 0 1
psychological reasons, psychological p ps psy psyc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 ,.(/) 5 10 0 0 0 0 1
withdrew d/t withdrew w wi wit with BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 / 1 6 0 0 0 0 1
AE: headache, ae: A AE AE: AE: BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 11 :,,- 4 9 0 0 0 0 1
piratory infections piratory p pi pir pira BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 11 (); 3 10 0 0 0 0 1
urticaria (n urticaria u ur urt urti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 11 () 2 5 0 0 0 0 1
40 w 40 4 40 40 40 BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 11 no 0 10 0 0 0 0 1
1906 1906 1906 1 19 190 1906 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 3 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 ()():- 6 10 0 1 1 0 1
Table 1 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 10 0 1 0 0 1
continued continued continued c co con cont BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 10 0 0 0 0 1
Study reference study S St Stu Stud BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 10 0 0 0 0 1
Dosing Dosing dosing D Do Dos Dosi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 1 no 0 1 0 0 0 0 1
Patients characteristics patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 1 (,, 3 9 0 0 0 0 1
affected areas, affected a af aff affe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 ,- 2 8 0 0 0 0 1
bidities, previously bidities, b bi bid bidi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 1 ,, 2 10 0 0 0 0 1
concomitant treatments) concomitant c co con conc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 1 ) 1 6 0 0 0 0 1
Treatment response treatment T Tr Tre Trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 2 no 0 10 0 0 0 0 1
effects effects effects e ef eff effe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 no 0 10 0 0 0 0 1
Timepoint(s) of timepoint(s) T Ti Tim Time BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 2 () 2 10 0 0 0 0 1
measurement measurement measurement m me mea meas BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 no 0 4 0 0 0 0 1
Hollywood et hollywood H Ho Hol Holl BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 2 .[]; 4 10 0 0 0 0 1
Ireland; case ireland; I Ir Ire Irel BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 2 ; 1 7 0 0 0 0 1
Not specified not N No Not Not BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 3 no 0 3 0 0 0 0 1
n = n n n n n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 3 3 (,),(-) 7 9 0 0 0 0 1
Disease severity: disease D Di Dis Dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 3 :(), 4 10 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 3 () 2 2 0 0 0 0 1
Comorbidities: CD comorbidities: C Co Com Como BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 :(); 4 8 0 0 0 0 1
gangrenosum, psoriasis gangrenosum, g ga gan gang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 3 ,() 3 7 0 0 0 0 1
PFT: ADA, pft: P PF PFT PFT: BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 6 :,(); 5 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 ();();, 7 10 0 0 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 ();() 5 8 0 0 0 0 1
Physician assessment physician P Ph Phy Phys BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 9 0 0 0 0 1
Improved: 75% improved: I Im Imp Impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 :(/) 4 10 0 0 0 0 1
Unchanged: 25% unchanged: U Un Unc Unch BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 :(/) 4 10 0 0 0 0 1
DLQI: 16.6 dlqi: D DL DLQ DLQI BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 8 :.(-) 5 10 0 0 0 0 1
10.25 (range 10.25 1 10 10. 10.2 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 9 .( 2 10 0 0 0 0 1
1-27) 1-27) 1-27) 1 1- 1-2 1-27 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 9 -) 2 1 0 0 0 0 1
Drug survival drug D Dr Dru Drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 9 no 0 4 0 0 0 0 1
6 mo: 6 6 6 6 6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 9 :.(/) 5 6 0 0 0 0 1
12 mo: 12 1 12 12 12 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 :.(/) 5 6 0 0 0 0 1
24 mo: 24 2 24 24 24 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 :(/) 4 5 0 0 0 0 1
36 mo: 36 3 36 36 36 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 9 :.(/) 5 5 0 0 0 0 1
AE: recurrent ae: A AE AE: AE: BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 9 :() 3 10 0 0 0 0 1
Mean tx mean M Me Mea Mean BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 11 : 1 10 0 0 0 0 1
16 mo 16 1 16 16 16 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 11 no 0 3 0 0 0 0 1
1907 1907 1907 1 19 190 1907 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 3 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 ()():- 6 10 0 1 1 0 1
Table 1 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 10 0 1 0 0 1
continued continued continued c co con cont BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 10 0 0 0 0 1
Study reference study S St Stu Stud BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 10 0 0 0 0 1
Dosing Dosing dosing D Do Dos Dosi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 1 0 0 0 0 1
Patients characteristics patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 (,, 3 9 0 0 0 0 1
affected areas, affected a af aff affe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ,- 2 8 0 0 0 0 1
bidities, previously bidities, b bi bid bidi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ,, 2 10 0 0 0 0 1
concomitant treatments) concomitant c co con conc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ) 1 6 0 0 0 0 1
Treatment response treatment T Tr Tre Trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 1 no 0 10 0 0 0 0 1
effects effects effects e ef eff effe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 no 0 10 0 0 0 0 1
Timepoint(s) of timepoint(s) T Ti Tim Time BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 1 () 2 10 0 0 0 0 1
measurement measurement measurement m me mea meas BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 no 0 4 0 0 0 0 1
Romaní et romaní R Ro Rom Roma BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 1 .[]; 4 10 0 0 0 0 1
Spain; case spain; S Sp Spa Spai BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 1 ; 1 7 0 0 0 0 1
IV loading iv I IV IV IV BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 1 no 0 9 0 0 0 0 1
(≤ 55 (≤ ( (≤ (≤ (≤ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 1 (: 2 5 0 0 0 0 1
260 mg; 260 2 26 260 260 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 1 ; 1 7 0 0 0 0 1
to ≤ to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 : 1 7 0 0 0 0 1
390 mg; 390 3 39 390 390 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 1 ;: 2 10 0 0 0 0 1
520 mg) 520 5 52 520 520 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 1 ) 1 5 0 0 0 0 1
90 mg 90 9 90 90 90 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 2 no 0 10 0 0 0 0 1
q8w SC q8w q q8 q8w q8w BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 2 no 0 1 0 0 0 0 1
n = n n n n n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 3 2 ,- 2 4 0 0 0 0 1
AA: axillae aa: A AA AA: AA: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 2 :();,(); 8 10 0 0 0 0 1
perineum (n perineum p pe per peri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 ();(); 6 8 0 0 0 0 1
genital (n genital g ge gen geni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ();();, 7 9 0 0 0 0 1
nape (n nape n na nap nape BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 () 2 2 0 0 0 0 1
Disease severity: disease D Di Dis Dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 2 :(), 4 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 () 2 2 0 0 0 0 1
Comorbidities: CD comorbidities: C Co Com Como BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 2 :();, 5 8 0 0 0 0 1
DM, HTN, dm, D DM DM, DM, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 5 ,,();- 6 10 0 0 0 0 1
thropathy (n thropathy t th thr thro BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 () 2 5 0 0 0 0 1
PFT: ADA pft: P PF PFT PFT: BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 5 :();(); 7 10 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 ();(); 6 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 ();,,, 6 9 0 0 0 0 1
MTX (n mtx M MT MTX MTX BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 5 (),,, 5 7 0 0 0 0 1
colectomy (n colectomy c co col cole BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 () 2 4 0 0 0 0 1
CT: oral/intralesional ct: C CT CT: CT: BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 6 :/ 2 10 0 0 0 0 1
abx for abx a ab abx abx BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 () 2 5 0 0 0 0 1
HiSCR: 21.4% hiscr: H Hi HiS HiSC BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 7 :.(/) 5 8 0 0 0 0 1
57.1% (8/14) 57.1% 5 57 57. 57.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 .(/) 4 6 0 0 0 0 1
IHS4: 76.9% ihs4: I IH IHS IHS4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 :.(/) 5 9 0 0 0 0 1
8 w, 8 8 8 8 8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 7 ,.(/) 5 7 0 0 0 0 1
PGA: 53.8% pga: P PG PGA PGA: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 7 :.(/), 6 10 0 0 0 0 1
50% (7/14) 50% 5 50 50% 50% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 (/) 3 5 0 0 0 0 1
VAS pain: vas V VA VAS VAS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 7 :(/) 4 9 0 0 0 0 1
at 8 at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 4 0 0 0 0 1
DLQI: 83.3% dlqi: D DL DLQ DLQI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 7 :.(/) 5 9 0 0 0 0 1
8 w, 8 8 8 8 8 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 9 ,.(/) 5 8 0 0 0 0 1
HiSCR and hiscr H Hi HiS HiSC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
DLQI and dlqi D DL DLQ DLQI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 9 :(/) 4 9 0 0 0 0 1
at 16 at a at at at BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 no 0 2 0 0 0 0 1
Only ≥ only O On Onl Only BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 10 no 0 8 0 0 0 0 1
and VAS and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 :.(/) 5 8 0 0 0 0 1
16 w 16 1 16 16 16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 10 no 0 1 0 0 0 0 1
91.6% had 91.6% 9 91 91. 91.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 10 .- 2 9 0 0 0 0 1
tant difference tant t ta tan tant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 ( 1 9 0 0 0 0 1
of 4) of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 ) 1 1 0 0 0 0 1
14.3% (2/14) 14.3% 1 14 14. 14.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 10 .(/)/ 5 10 0 0 0 0 1
efficacy or efficacy e ef eff effi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 no 0 8 0 0 0 0 1
8 w, 8 8 8 8 8 BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 11 , 1 10 0 0 0 0 1
1908 1908 1908 1 19 190 1908 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 3 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 ()():- 6 10 0 1 1 0 1
Table 1 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 1 0 0 1
continued continued continued c co con cont BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 0 0 0 1
Study reference study S St Stu Stud BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 0 0 0 1
Dosing Dosing dosing D Do Dos Dosi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 1 0 0 0 0 1
Patients characteristics patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 (,, 3 9 0 0 0 0 1
affected areas, affected a af aff affe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,- 2 8 0 0 0 0 1
bidities, previously bidities, b bi bid bidi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ,, 2 10 0 0 0 0 1
concomitant treatments) concomitant c co con conc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ) 1 6 0 0 0 0 1
Treatment response treatment T Tr Tre Trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 1 no 0 10 0 0 0 0 1
effects effects effects e ef eff effe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 no 0 10 0 0 0 0 1
Timepoint(s) of timepoint(s) T Ti Tim Time BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 2 () 2 10 0 0 0 0 1
measurement measurement measurement m me mea meas BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 no 0 4 0 0 0 0 1
Montero-Vilchez et montero-vilchez M Mo Mon Mont BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 2 -. 2 10 0 0 0 0 1
[8]; Spain; [8]; [ [8 [8] [8]; BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 2 [];; 4 10 0 0 0 0 1
Induction dose: induction I In Ind Indu BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 : 1 10 0 0 0 0 1
45 mg 45 4 45 45 45 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 3 no 0 10 0 0 0 0 1
(weight-based) (weight-based) (weight-based) ( (w (we (wei BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 3 (-) 3 10 0 0 0 0 1
SC → sc S SC SC SC BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 3 no 0 4 0 0 0 0 1
45 mg 45 4 45 45 45 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 3 no 0 10 0 0 0 0 1
SC SC sc S SC SC SC BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 3 no 0 0 0 0 0 0 1
n = n n n n n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 4 3 (,),( 5 10 0 0 0 0 1
35-44) 35-44) 35-44) 3 35 35- 35-4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 -) 2 10 0 0 0 0 1
AA: Groin aa: A AA AA: AA: BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 :();,(); 8 10 0 0 0 0 1
genital, face, genital, g ge gen geni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ,,();, 6 8 0 0 0 0 1
breast (n breast b br bre brea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 () 2 3 0 0 0 0 1
Disease severity: disease D Di Dis Dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 :(), 4 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 () 2 1 0 0 0 0 1
Comorbidities: acne comorbidities: C Co Com Como BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 :, 2 8 0 0 0 0 1
(n = (n ( (n (n (n BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 ();();, 7 10 0 0 0 0 1
palmoplantar pustulosis, palmoplantar p pa pal palm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 , 1 9 0 0 0 0 1
dermatitis (n dermatitis d de der derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 () 2 5 0 0 0 0 1
PFT: retinoids, pft: P PF PFT PFT: BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 :,,(); 6 8 0 0 0 0 1
surgery (n surgery s su sur surg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 (),(); 6 10 0 0 0 0 1
IFX (n ifx I IF IFX IFX BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 ();();, 7 9 0 0 0 0 1
interferon, phototherapy interferon, i in int inte BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 ,() 3 7 0 0 0 0 1
HS-PGA HS-PGA hs-pga H HS HS- HS-P BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 9 - 1 2 0 0 0 0 1
Improved (decrease improved I Im Imp Impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 9 (): 3 10 0 0 0 0 1
(7/10) (7/10) (7/10) ( (7 (7/ (7/1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 9 (/) 3 2 0 0 0 0 1
Unchanged: 30% unchanged: U Un Unc Unch BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 9 :(/) 4 6 0 0 0 0 1
NPRS NPRS nprs N NP NPR NPRS BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 1 0 0 0 0 1
Improved (decrease improved I Im Imp Impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 10 (): 3 10 0 0 0 0 1
(8/10) (8/10) (8/10) ( (8 (8/ (8/1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 (/) 3 1 0 0 0 0 1
Unchanged: 20% unchanged: U Un Unc Unch BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 10 :(/) 4 6 0 0 0 0 1
Median tx median M Me Med Medi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 : 1 10 0 0 0 0 1
48 w 48 4 48 48 48 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 11 no 0 2 0 0 0 0 1
1909 1909 1909 1 19 190 1909 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 ()():- 6 10 0 1 1 0 1
Table 1 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 1 0 0 1
continued continued continued c co con cont BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 0 0 0 1
Study reference study S St Stu Stud BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 0 0 0 1
Dosing Dosing dosing D Do Dos Dosi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 1 0 0 0 0 1
Patients characteristics patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 (,, 3 9 0 0 0 0 1
affected areas, affected a af aff affe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,- 2 8 0 0 0 0 1
bidities, previously bidities, b bi bid bidi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ,, 2 10 0 0 0 0 1
concomitant treatments) concomitant c co con conc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ) 1 6 0 0 0 0 1
Treatment response treatment T Tr Tre Trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 1 no 0 10 0 0 0 0 1
effects effects effects e ef eff effe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 no 0 10 0 0 0 0 1
Timepoint(s) of timepoint(s) T Ti Tim Time BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 1 () 2 10 0 0 0 0 1
measurement measurement measurement m me mea meas BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 no 0 4 0 0 0 0 1
Valenzuela-Ubiña et valenzuela-ubiña V Va Val Vale BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 1 -. 2 10 0 0 0 0 1
[23]; Spain; [23]; [ [2 [23 [23] BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 [];; 4 10 0 0 0 0 1
90 mg 90 9 90 90 90 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 1 no 0 6 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 1 (; 2 10 0 0 0 0 1
an IV an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 1 no 0 7 0 0 0 0 1
dose), 45 dose), d do dos dose BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 1 ), 2 6 0 0 0 0 1
q12w SC q12w q q1 q12 q12w BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 (; 2 8 0 0 0 0 1
1 received 1 1 1 1 1 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 2 no 0 3 0 0 0 0 1
loading dose) loading l lo loa load BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 ) 1 3 0 0 0 0 1
n = n n n n n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 4 2 (,),. 5 8 0 0 0 0 1
Disease severity: disease D Di Dis Dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 2 :(), 4 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 2 () 2 1 0 0 0 0 1
AA: inguinal, aa: A AA AA: AA: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 2 :,(); 5 8 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 2 ();,,(); 8 10 0 0 0 0 1
gluteal, intermammary, gluteal, g gl glu glut BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 2 ,, 2 7 0 0 0 0 1
(n = (n ( (n (n (n BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 () 2 2 0 0 0 0 1
Comorbidities: psoriasis, comorbidities: C Co Com Como BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 :,(); 5 10 0 0 0 0 1
UC, spondyloarthropathy, uc, U UC UC, UC, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 ,,,, 4 9 0 0 0 0 1
SLE (n sle S SL SLE SLE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 () 2 2 0 0 0 0 1
PFT: oral pft: P PF PFT PFT: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 :();(); 7 9 0 0 0 0 1
surgery (n surgery s su sur surg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ();,, 5 10 0 0 0 0 1
IFX (n ifx I IF IFX IFX BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 ();,, 5 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ();(); 6 8 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ();,,, 6 9 0 0 0 0 1
steroids (n steroids s st ste ster BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ();,, 5 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 () 2 10 0 0 0 0 1
HiSCR: 90% hiscr: H Hi HiS HiSC BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 6 :(/), 5 8 0 0 0 0 1
lower dose lower l lo low lowe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 7 0 0 0 0 1
Hurley stage hurley H Hu Hur Hurl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 4 6 (/) 3 10 0 0 0 0 1
HS-PGA decreased hs-pga H HS HS- HS-P BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 6 - 1 8 0 0 0 0 1
point in point p po poi poin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 (/) 3 5 0 0 0 0 1
100% (10/10) 100% 1 10 100 100% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 6 (/) 3 7 0 0 0 0 1
analytical parameters analytical a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 9 0 0 0 0 1
inflammation (ASPI) inflammation i in inf infl BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 () 2 5 0 0 0 0 1
Pt with pt P Pt Pt Pt BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 no 0 10 0 0 0 0 1
Mean treatment mean M Me Mea Mean BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 : 1 10 0 0 0 0 1
17.6 mo 17.6 1 17 17. 17.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 . 1 3 0 0 0 0 1
Mean response mean M Me Mea Mean BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 : 1 9 0 0 0 0 1
4.7 mo 4.7 4 4. 4.7 4.7 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 . 1 3 0 0 0 0 1
Jiang et jiang J Ji Jia Jian BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 4 8 .[];; 5 10 0 0 0 0 1
case series case c ca cas case BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 8 no 0 4 0 0 0 0 1
90 mg 90 9 90 90 90 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (), 3 4 0 0 0 0 1
90 mg 90 9 90 90 90 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 () 2 4 0 0 0 0 1
n = n n n n n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 4 9 (,),.. 6 10 0 0 0 0 1
Disease severity: disease D Di Dis Dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 9 :() 3 9 0 0 0 0 1
PFT: ADA pft: P PF PFT PFT: BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 9 :();() 6 7 0 0 0 0 1
IHS4: -36.1%, ihs4: I IH IHS IHS4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 :-.,(/) 7 8 0 0 0 0 1
improved at improved i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 10 -,(/) 5 10 0 0 0 0 1
improved at improved i im imp impr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 10 - 1 6 0 0 0 0 1
VAS pain: vas V VA VAS VAS BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 11 :-. 3 4 0 0 0 0 1
AN count: an A AN AN AN BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 1 0 0 0 0 0 4 11 :(/) 4 9 0 0 0 0 1
after 8-12 after a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 11 -,(/) 5 10 0 0 0 0 1
at 13-21w at a at at at BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 11 - 1 3 0 0 0 0 1
8-12 w, 8-12 8 8- 8-1 8-12 BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 -,- 3 10 0 0 0 0 1
1910 1910 1910 1 19 191 1910 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 5 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 ()():- 6 10 0 1 1 0 1
Table 1 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 10 0 1 0 0 1
continued continued continued c co con cont BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 10 0 0 0 0 1
Study reference study S St Stu Stud BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 10 0 0 0 0 1
Dosing Dosing dosing D Do Dos Dosi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 1 0 0 0 0 1
Patients characteristics patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 (,, 3 9 0 0 0 0 1
affected areas, affected a af aff affe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,- 2 8 0 0 0 0 1
bidities, previously bidities, b bi bid bidi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ,, 2 10 0 0 0 0 1
concomitant treatments) concomitant c co con conc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ) 1 6 0 0 0 0 1
Treatment response treatment T Tr Tre Trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 10 0 0 0 0 1
effects effects effects e ef eff effe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 10 0 0 0 0 1
Timepoint(s) of timepoint(s) T Ti Tim Time BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 () 2 10 0 0 0 0 1
measurement measurement measurement m me mea meas BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 4 0 0 0 0 1
Sanchez-Martinez et sanchez-martinez S Sa San Sanc BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 -. 2 10 0 0 0 0 1
[24]; Spain; [24]; [ [2 [24 [24] BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 1 [];; 4 10 0 0 0 0 1
IV loading iv I IV IV IV BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 no 0 8 0 0 0 0 1
dose (weight dose d do dos dose BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 ( 1 10 0 0 0 0 1
adjusted) → adjusted) a ad adj adju BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 1 ) 1 9 0 0 0 0 1
90 mg 90 9 90 90 90 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 1 no 0 4 0 0 0 0 1
q8w SC q8w q q8 q8w q8w BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 no 0 1 0 0 0 0 1
n = n n n n n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 5 2 (,),( 5 10 0 0 0 0 1
31-59) 31-59) 31-59) 3 31 31- 31-5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 -) 2 1 0 0 0 0 1
Disease severity: disease D Di Dis Dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 2 :() 3 10 0 0 0 0 1
Comorbidities: DS, comorbidities: C Co Com Como BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 2 :,, 3 9 0 0 0 0 1
hypothyroidism, CD, hypothyroidism, h hy hyp hypo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 2 ,,() 4 8 0 0 0 0 1
PFT: abx, pft: P PF PFT PFT: BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 3 :,,();- 7 8 0 0 0 0 1
gery, systemic gery, g ge ger gery BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 ,();, 5 8 0 0 0 0 1
finasteride, topical finasteride, f fi fin fina BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 ,(); 4 10 0 0 0 0 1
(n = (n ( (n (n (n BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 () 2 1 0 0 0 0 1
CT: ILK, ct: C CT CT: CT: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 3 :,,(); 6 10 0 0 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 () 2 1 0 0 0 0 1
HiSCR: 50% hiscr: H Hi HiS HiSC BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 4 :(/) 4 6 0 0 0 0 1
IHS4: 83.3% ihs4: I IH IHS IHS4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 :.(/) 5 10 0 0 0 0 1
12 w 12 1 12 12 12 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 4 no 0 10 0 0 0 0 1
Gulliver et gulliver G Gu Gul Gull BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 4 .[];- 5 10 0 0 0 0 1
mark; case mark; m ma mar mark BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 ; 1 5 0 0 0 0 1
45 mg 45 4 45 45 45 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 5 ,, 2 9 0 0 0 0 1
and 4mo and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 6 0 0 0 0 1
q3mo; dose q3mo; q q3 q3m q3mo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 ; 1 5 0 0 0 0 1
increased to increased i in inc incr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 10 0 0 0 0 1
at 6 at a at at at BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 10 0 0 0 0 1
n = n n n n n BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 5 5 no 0 1 0 0 0 0 1
n = n n n n n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 5 5 (,),,, 6 7 0 0 0 0 1
AA: Axillae, aa: A AA AA: AA: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 5 :,();,, 7 10 0 0 0 0 1
gluteal (n gluteal g gl glu glut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 () 2 3 0 0 0 0 1
Disease severity: disease D Di Dis Dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 :(), 4 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 () 2 1 0 0 0 0 1
PFT: oral pft: P PF PFT PFT: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 5 :();,, 6 9 0 0 0 0 1
retinoids (n retinoids r re ret reti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 ();, 4 8 0 0 0 0 1
resorcinol, IFX, resorcinol, r re res reso BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 ,,,, 4 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 7 () 2 10 0 0 0 0 1
Physician assessment physician P Ph Phy Phys BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 7 no 0 5 0 0 0 0 1
Complete response: complete C Co Com Comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 7 :.(/) 5 8 0 0 0 0 1
Partial response: partial P Pa Par Part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 7 :.(/) 5 10 0 0 0 0 1
increasing dose increasing i in inc incr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 no 0 6 0 0 0 0 1
No response: no N No No No BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 :.(/) 5 6 0 0 0 0 1
AE: cystitis, ae: A AE AE: AE: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 8 :,, 3 9 0 0 0 0 1
arthritis, bacterial arthritis, a ar art arth BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 8 , 1 10 0 0 0 0 1
(n = (n ( (n (n (n BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 9 () 2 10 0 0 0 0 1
6 mo 6 6 6 6 6 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 9 no 0 10 0 0 0 0 1
Martin-Ezquerra et martin-ezquerra M Ma Mar Mart BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 -. 2 10 0 0 0 0 1
[26]; Spain; [26]; [ [2 [26 [26] BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 [];; 4 10 0 0 0 0 1
Not specified not N No Not Not BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 9 no 0 3 0 0 0 0 1
n = n n n n n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 5 9 (- 2 10 0 0 0 0 1
second-line tx second-line s se sec seco BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 -) 2 5 0 0 0 0 1
PFT: surgery pft: P PF PFT PFT: BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 :();-- 6 10 0 0 0 0 1
tor (n tor t to tor tor BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 10 () 2 3 0 0 0 0 1
Physician and physician P Ph Phy Phys BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 10 no 0 10 0 0 0 0 1
UST as ust U US UST UST BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 - 1 6 0 0 0 0 1
Complete response: complete C Co Com Comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 10 :(/) 4 8 0 0 0 0 1
Partial response: partial P Pa Par Part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 10 :(/) 4 8 0 0 0 0 1
UST as ust U US UST UST BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 - 1 6 0 0 0 0 1
Partial response partial P Pa Par Part BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 10 (/) 3 8 0 0 0 0 1
Mean duration mean M Me Mea Mean BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 no 0 8 0 0 0 0 1
tx: 18 tx: t tx tx: tx: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 11 :(), 4 9 0 0 0 0 1
unspecified (n unspecified u un uns unsp BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 11 () 2 10 0 0 0 0 1
1911 1911 1911 1 19 191 1911 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 5 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 ()():- 6 10 0 1 1 0 1
Table 1 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 10 0 1 0 0 1
continued continued continued c co con cont BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 10 0 0 0 0 1
Study reference study S St Stu Stud BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 10 0 0 0 0 1
Dosing Dosing dosing D Do Dos Dosi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 1 0 0 0 0 1
Patients characteristics patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 (,, 3 9 0 0 0 0 1
affected areas, affected a af aff affe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,- 2 8 0 0 0 0 1
bidities, previously bidities, b bi bid bidi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ,, 2 10 0 0 0 0 1
concomitant treatments) concomitant c co con conc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ) 1 6 0 0 0 0 1
Treatment response treatment T Tr Tre Trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 10 0 0 0 0 1
effects effects effects e ef eff effe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 10 0 0 0 0 1
Timepoint(s) of timepoint(s) T Ti Tim Time BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 () 2 10 0 0 0 0 1
measurement measurement measurement m me mea meas BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 4 0 0 0 0 1
Scholl et scholl S Sc Sch Scho BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 5 1 .[];- 5 10 0 0 0 0 1
many; case many; m ma man many BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 ; 1 6 0 0 0 0 1
IV loading iv I IV IV IV BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 no 0 9 0 0 0 0 1
(≤ 55 (≤ ( (≤ (≤ (≤ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 (: 2 5 0 0 0 0 1
260 mg; 260 2 26 260 260 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 1 ; 1 7 0 0 0 0 1
to ≤ to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 : 1 7 0 0 0 0 1
390 mg; 390 3 39 390 390 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 1 ;: 2 10 0 0 0 0 1
520 mg) 520 5 52 520 520 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 1 ) 1 5 0 0 0 0 1
90 mg 90 9 90 90 90 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 2 no 0 10 0 0 0 0 1
SC at sc S SC SC SC BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 2 no 0 2 0 0 0 0 1
8 → 8 8 8 8 8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 2 no 0 0 0 0 0 0 1
90 mg 90 9 90 90 90 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 2 no 0 2 0 0 0 0 1
q12w as q12w q q1 q12 q12w BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 no 0 4 0 0 0 0 1
n = n n n n n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 5 2 (,),,, 6 8 0 0 0 0 1
Disease severity: disease D Di Dis Dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 2 :(), 4 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 2 () 2 1 0 0 0 0 1
PFT: Resistant pft: P PF PFT PFT: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 2 : 1 9 0 0 0 0 1
first-or second-line first-or f fi fir firs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 -- 2 9 0 0 0 0 1
CT: deroofing ct: C CT CT: CT: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 2 :();,- 6 10 0 0 0 0 1
sion (n sion s si sio sion BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 2 () 2 2 0 0 0 0 1
100% (3/3) 100% 1 10 100 100% BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 (/) 3 9 0 0 0 0 1
Pt 1: pt P Pt Pt Pt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 4 : 1 9 0 0 0 0 1
worsened DLQI worsened w wo wor wors BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 9 0 0 0 0 1
deroofing at deroofing d de der dero BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 ;- 2 10 0 0 0 0 1
sion at sion s si sio sion BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 no 0 4 0 0 0 0 1
Pt 2: pt P Pt Pt Pt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 4 :, 2 10 0 0 0 0 1
mHSS, SAHS, mhss, m mH mHS mHSS BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 ,, 2 5 0 0 0 0 1
Pt 3: pt P Pt Pt Pt BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 5 :; 2 10 0 0 0 0 1
6mo, SAHS 6mo, 6 6m 6mo 6mo, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 , 1 7 0 0 0 0 1
by 30% by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 8 0 0 0 0 1
remained unchanged remained r re rem rema BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 7 0 0 0 0 1
oral abx oral o or ora oral BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 5 /- 2 10 0 0 0 0 1
sion; after sion; s si sio sion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 ;,- 3 9 0 0 0 0 1
ment in ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 ,, 2 10 0 0 0 0 1
disease activity, disease d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 , 1 9 0 0 0 0 1
count count count c co cou coun BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 1 0 0 0 0 1
q3mo q3mo q3mo q q3 q3m q3mo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 6 no 0 10 0 0 0 0 1
AA affected aa A AA AA AA BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 6 , 1 10 0 0 0 0 1
Abx antibiotics, abx A Ab Abx Abx BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 6 , 1 4 0 0 0 0 1
ADA adalimumab, ada A AD ADA ADA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 6 6 , 1 4 0 0 0 0 1
AE adverse ae A AE AE AE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 6 , 1 4 0 0 0 0 1
AN abscesses an A AN AN AN BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 1 1 0 0 0 0 0 6 6 , 1 10 0 0 0 0 1
ANK anakinra, ank A AN ANK ANK BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 6 , 1 7 0 0 0 0 1
AZA azathioprine, aza A AZ AZA AZA BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 6 , 1 10 0 0 0 0 1
CD Crohn's cd C CD CD CD BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 ' 1 10 0 1 0 0 1
disease, disease, disease, d di dis dise BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 , 1 3 0 0 0 0 1
CT concomitant ct C CT CT CT BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 , 1 10 0 0 0 0 1
DLP dyslipidemia, dlp D DL DLP DLP BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 , 1 4 0 0 0 0 1
DLQI dermatology dlqi D DL DLQ DLQI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 , 1 10 0 0 0 0 1
DM diabetes dm D DM DM DM BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 , 1 10 0 0 0 0 1
DS Down ds D DS DS DS BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 , 1 10 0 0 0 0 1
d/t due d/t d d/ d/t d/t BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 7 /, 2 10 0 1 0 0 1
F female, f F F F F BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 7 , 1 10 0 1 0 0 1
HiSCR hidradenitis hiscr H Hi HiS HiSC BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 , 1 10 0 0 0 0 1
HTN hypertension, htn H HT HTN HTN BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 , 1 2 0 0 0 0 1
I&D incision i&d I I& I&D I&D BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 , 1 4 0 0 0 0 1
IHS4 international ihs4 I IH IHS IHS4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 , 1 10 0 0 0 0 1
IFX infliximab, ifx I IF IFX IFX BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 , 1 3 0 0 0 0 1
ILK intralesional ilk I IL ILK ILK BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 6 8 , 1 6 0 0 0 0 1
IPL-EPI intense ipl-epi I IP IPL IPL- BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 -, 2 10 0 0 0 0 1
IV intravenous, iv I IV IV IV BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 , 1 10 0 0 0 0 1
kg kilogram, kg k kg kg kg BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 8 , 1 10 0 0 0 0 1
L left, l L L L L BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 8 , 1 5 0 0 0 0 1
M male, m M M M M BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 8 , 1 5 0 0 0 0 1
mg milligram, mg m mg mg mg BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 8 , 1 10 0 0 0 0 1
mHSLASI modified mhslasi m mH mHS mHSL BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 9 no 0 10 0 1 0 0 1
hidradenitis suppurativa hidradenitis h hi hid hidr BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 9 , 1 10 0 0 0 0 1
mo month, mo m mo mo mo BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 6 9 , 1 3 0 0 0 0 1
mSS modified mss m mS mSS mSS BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 9 , 1 10 0 0 0 0 1
MTX methotrexate, mtx M MT MTX MTX BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 9 , 1 10 0 0 0 0 1
N number, n N N N N BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 9 , 1 4 0 0 0 0 1
OCP oral ocp O OC OCP OCP BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 9 , 1 10 0 0 0 0 1
PCOS pol- pcos P PC PCO PCOS BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 9 - 1 10 0 1 0 0 1
ycystic ovarian ycystic y yc ycy ycys BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 9 , 1 7 0 0 0 0 1
PFT previously pft P PF PFT PFT BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 9 , 1 10 0 0 0 0 1
PGA physician pga P PG PGA PGA BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 , 1 10 0 0 0 0 1
Pt patient, pt P Pt Pt Pt BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 , 1 10 0 0 0 0 1
R right, r R R R R BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 10 , 1 3 0 0 0 0 1
RA rheumatoid ra R RA RA RA BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 , 1 10 0 0 0 0 1
SAHS severity sahs S SA SAH SAHS BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
of hidradenitis of o of of of BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 , 1 10 0 0 0 0 1
SC subcutaneous, sc S SC SC SC BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 , 1 10 0 0 0 0 1
SFZ sulfasalazine, sfz S SF SFZ SFZ BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 , 1 5 0 0 0 0 1
SLE systemic sle S SL SLE SLE BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 , 1 10 0 0 0 0 1
TNF tumor tnf T TN TNF TNF BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 11 , 1 10 0 0 0 0 1
TX treatment, tx T TX TX TX BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 11 , 1 6 0 0 0 0 1
UC ulcerative uc U UC UC UC BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 11 , 1 10 0 0 0 0 1
UST ustekinumab, ust U US UST UST BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 11 , 1 6 0 0 0 0 1
VAS visual vas V VA VAS VAS BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 11 , 1 10 0 0 0 0 1
w week w w w w w BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 6 11 no 0 10 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 6 11 no 0 10 0 1 0 0 1
High risk high H Hi Hig High BLOCKSTART PAGEEND SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 6 11 no 0 10 0 0 0 0 1
1912 1912 1912 1 19 191 1912 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 6 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 ()():- 6 10 0 1 1 0 1
concomitant treatments, concomitant c co con conc BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,- 2 8 0 0 0 0 1
bidities, responses bidities, b bi bid bidi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,, 3 9 0 0 0 0 1
and study and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 9 0 0 0 0 1
terms of terms t te ter term BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 9 0 0 0 0 1
a high a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 6 0 . 1 4 0 0 0 0 1
Across all across A Ac Acr Acro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 8 0 0 0 0 1
20 to 20 2 20 20 20 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 0 . 1 8 0 0 0 0 1
reported in reported r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
series as series s se ser seri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,,.[-],- 8 9 0 0 0 0 1
tively. Of tively. t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 .- 2 9 0 0 0 0 1
der data, der d de der der BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,.(/). 6 9 0 0 0 0 1
HS severity hs H HS HS HS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
patients across patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 9 0 0 0 0 1
of patients of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 (., 3 9 0 0 0 0 1
56/68) followed 56/68) 5 56 56/ 56/6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 /)(.,/).- 9 9 0 0 0 0 1
viously failed viously v vi vio viou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
studies and studies s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 9 0 0 0 0 1
or systemic or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,(,- 4 9 0 0 0 0 1
temic, or temic, t te tem temi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,),,, 5 9 0 0 0 0 1
certolizumab, etanercept, certolizumab, c ce cer cert BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,,, 4 9 0 0 0 0 1
methotrexate, azathioprine, methotrexate, m me met meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,,- 4 8 0 0 0 0 1
fasalazine, oral fasalazine, f fa fas fasa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,,, 4 9 0 0 0 0 1
metformin, spironolactone, metformin, m me met metf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,,- 4 8 0 0 0 0 1
feron, intense feron, f fe fer fero BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,- 3 9 0 0 0 0 1
totherapy, deroofing, totherapy, t to tot toth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,, 3 9 0 0 0 0 1
surgery. The surgery. s su sur surg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 .(.,/) 6 9 0 0 0 0 1
had previously had h ha had had BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 - 1 9 0 0 0 0 1
ment. Nearly ment. m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 .-(.,/) 7 8 0 0 0 0 1
failed adalimumab, failed f fa fai fail BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,- 2 8 0 0 0 0 1
(36.4%, 32/88) (36.4%, ( (3 (36 (36. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 (.,/).- 7 8 0 0 0 0 1
bidities were bidities b bi bid bidi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
studies; 23.3% studies; s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ;.(/)' 6 8 0 0 0 0 1
ulcerative colitis, ulcerative u ul ulc ulce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,.(/). 6 9 0 0 0 0 1
Concomitant treatments concomitant C Co Con Conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
include topical include i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,- 2 9 0 0 0 0 1
esional steroids, esional e es esi esio BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,- 3 9 0 0 0 0 1
biotics, oral biotics, b bi bio biot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,,. 4 9 0 0 0 0 1
Dosing of dosing D Do Dos Dosi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 () 2 7 0 0 0 0 1
in four in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 0 ,, 2 9 0 0 0 0 1
45 mg 45 4 45 45 45 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 0 ,- 2 9 0 0 0 0 1
ies. Across ies. i ie ies ies. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ., 2 9 0 0 0 0 1
ustekinumab maintenance ustekinumab u us ust uste BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 8 0 0 0 0 1
every 4 every e ev eve ever BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 8 0 0 0 0 1
was delivered was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
subcutaneously in subcutaneously s su sub subc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 . 1 9 0 0 0 0 1
for efficacy for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 0 0 0 0 1
to 18 to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 .- 2 9 0 0 0 0 1
reported outcome reported r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 -- 2 8 0 0 0 0 1
ysis of ysis y ys ysi ysis BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 (),(),- 7 10 0 0 0 0 1
Global Assessment global G Gl Glo Glob BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 6 (), 3 8 0 0 0 0 1
Severity Score severity S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 6 ()().- 6 8 0 0 0 0 1
all response all a al all all BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 - 1 8 0 0 0 0 1
(IV) loading (iv) ( (I (IV (IV) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 6 () 2 7 0 0 0 0 1
8-12 weeks 8-12 8 8- 8-1 8-12 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 6 -(). 4 7 0 0 0 0 1
(17/26); the (17/26); ( (1 (17 (17/ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 6 (/); 4 8 0 0 0 0 1
followed by followed f fo fol foll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 no 0 7 0 0 0 0 1
every 8-12 every e ev eve ever BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 -.(/). 6 6 0 0 0 0 1
On the on O On On On BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 6 - 1 8 0 0 0 0 1
included studies, included i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 , 1 8 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 no 0 8 0 0 0 0 1
67% (95% 67% 6 67 67% 67% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 6 (.-.).- 7 8 0 0 0 0 1
geneity was geneity g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 6 (, 2 8 0 0 0 0 1
p = p p p p p BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 7 6 .)(.). 6 10 0 0 0 0 1
a response a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 6 . 1 9 0 0 0 0 1
were reported were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 .(/) 4 8 0 0 0 0 1
studies. These studies. s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 .,, 3 9 0 0 0 0 1
respiratory infection, respiratory r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 ,,,- 4 9 0 0 0 0 1
form dermatitis, form f fo for form BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 ,,- 3 9 0 0 0 0 1
tion, and tion, t ti tio tion BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 6 ,. 2 5 0 0 0 0 1
DISCUSSION DISCUSSION discussion D DI DIS DISC BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 no 0 10 0 0 0 0 1
Our study our O Ou Our Our BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 no 0 8 0 0 0 0 1
effective and effective e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 no 0 9 0 0 0 0 1
with recalcitrant, with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 ,-. 3 8 0 0 0 0 1
fixed-effects meta-analysis fixed-effects f fi fix fixe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 -- 2 8 0 0 0 0 1
response rate response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 , 1 8 0 0 0 0 1
patients had patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 no 0 10 0 0 0 0 1
biologic agent. biologic b bi bio biol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 9 . 1 9 0 0 0 0 1
only 4.5% only o on onl only BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 . 1 9 0 0 0 0 1
treatment. treatment. treatment. t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 . 1 2 0 0 0 0 1
Although the although A Al Alt Alth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 no 0 8 0 0 0 0 1
remains unclear, remains r re rem rema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 ,- 2 9 0 0 0 0 1
matory cytokines matory m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 9 no 0 10 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 9 . 1 10 0 0 0 0 1
Disproportionately high disproportionately D Di Dis Disp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 - 1 8 0 0 0 0 1
IL-23 have il-23 I IL IL- IL-2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 -,- 3 9 0 0 0 0 1
ing potential ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 7 9 no 0 9 0 0 0 0 1
block these block b bl blo bloc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 9 - 1 8 0 0 0 0 1
stream maturation stream s st str stre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 --- 3 9 0 0 0 0 1
cells [12]. cells c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 []. 3 2 0 0 0 0 1
The optimal the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 no 0 8 0 0 0 0 1
in patients in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 9 . 1 10 0 0 0 0 1
Jiang et jiang J Ji Jia Jian BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 7 9 .'- 3 9 0 0 0 0 1
dose, high-frequency dose, d do dos dose BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 ,-- 3 9 0 0 0 0 1
tive in tive t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 9 no 0 10 0 0 0 0 1
with HS, with w wi wit with BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 , 1 9 0 0 0 0 1
1913 1913 1913 1 19 191 1913 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 7 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ()():- 6 10 0 1 1 0 1
sample size sample s sa sam samp BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 0 [].- 4 10 0 0 0 0 1
atic review atic a at ati atic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 -., 3 9 0 0 0 0 1
increasing the increasing i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
6 weeks 6 6 6 6 6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 0 ,/ 2 9 0 0 0 0 1
reinduction, led reinduction, r re rei rein BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 , 1 9 0 0 0 0 1
of 925 of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 '- 2 9 0 0 0 0 1
ously had ously o ou ous ousl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 - 1 9 0 0 0 0 1
ard ustekinumab ard a ar ard ard BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 7 0 [].- 4 8 0 0 0 0 1
ing the ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
every 12 every e ev eve ever BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
to be to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 []. 3 9 0 0 0 0 1
More investigation more M Mo Mor More BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
potential advantages potential p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 9 0 0 0 0 1
ers or ers e er ers ers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 - 1 9 0 0 0 0 1
ment. Use ment. m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ., 2 9 0 0 0 0 1
such as such s su suc such BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 [], 3 9 0 0 0 0 1
also be also a al als also BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
to monitor to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 6 0 0 0 0 1
In addition, in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 0 , 1 8 0 0 0 0 1
the IV the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
initial SC initial i in ini init BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 9 0 0 0 0 1
ustekinumab trough ustekinumab u us ust uste BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
were comparable were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ' 1 8 0 0 0 0 1
disease who disease d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 7 0 0 0 0 1
pared with pared p pa par pare BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ' 1 8 0 0 0 0 1
who received who w wh who who BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
clinical trial clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 []., 4 10 0 0 0 0 1
ustekinumab may ustekinumab u us ust uste BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
consideration for consideration c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 9 0 0 0 0 1
financial, or financial, f fi fin fina BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 9 0 0 0 0 1
infusion center infusion i in inf infu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 9 0 0 0 0 1
ing, but ing, i in ing ing, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ,. 2 7 0 0 0 0 1
There is there T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 8 0 0 0 0 1
ment of ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ()- 3 8 0 0 0 0 1
peutic drug peutic p pe peu peut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
in HS. in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 0 ..' 3 9 0 0 0 0 1
of 491 of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
ustekinumab found ustekinumab u us ust uste BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
in 3.5% in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 0 .. 2 9 0 0 0 0 1
levels during levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
with better with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
of treatment, of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 9 0 0 0 0 1
levels during levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
may be may m ma may may BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 1 0 0 7 0 no 0 9 0 0 0 0 1
[17]. A [17]. [ [1 [17 [17] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 [].. 4 8 0 0 0 0 1
reported that reported r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 .- 2 8 0 0 0 0 1
of patients of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 8 0 0 0 0 1
riasis compared riasis r ri ria rias BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 .-. 3 9 0 0 0 0 1
infliximab, 0-18.3% infliximab, i in inf infl BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ,-.,- 5 8 0 0 0 0 1
on adalimumab on o on on on BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 [].- 4 9 0 0 0 0 1
cate that cate c ca cat cate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
risk of risk r ri ris risk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
are commonly are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 8 0 0 0 0 1
and infliximab, and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,- 2 8 0 0 0 0 1
standing of standing s st sta stan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ' 1 8 0 0 0 0 1
and optimal and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
clinicians in clinicians c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
response to response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 . 1 5 0 0 0 0 1
This study this T Th Thi This BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
providing an providing p pr pro prov BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 8 0 0 0 0 1
well as well w we wel well BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
use in use u us use use BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,- 2 9 0 0 0 0 1
numab in numab n nu num numa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 . 1 8 0 0 0 0 1
systematic review systematic s sy sys syst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 8 0 0 0 0 1
Montero-Vilchez et montero-vilchez M Mo Mon Mont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 -. 2 9 0 0 0 0 1
patients exhibited patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 [], 3 9 0 0 0 0 1
note, case note, n no not note BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,, 2 10 0 0 0 0 1
which could which w wh whi whic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 8 0 0 0 0 1
favorable response favorable f fa fav favo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 . 1 9 0 0 0 0 1
ustekinumab in ustekinumab u us ust uste BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
drug survival drug d dr dru drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 . 1 8 0 0 0 0 1
found that, found f fo fou foun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 , 1 9 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 , 1 9 0 0 0 0 1
between ustekinumab, between b be bet betw BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,,- 3 8 0 0 0 0 1
liximab; the liximab; l li lix lixi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 ; 1 9 0 0 0 0 1
for ustekinumab for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 []. 3 8 0 0 0 0 1
studies on studies s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
its real-world its i it its its BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 -. 2 10 0 0 0 0 1
that adverse that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
among patients among a am amo amon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 - 1 8 0 0 0 0 1
numab and numab n nu num numa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 - 1 9 0 0 0 0 1
profile of profile p pr pro prof BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 []. 3 9 0 0 0 0 1
cohort study cohort c co coh coho BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 ,- 2 9 0 0 0 0 1
matory bowel matory m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
was associated was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 - 1 9 0 0 0 0 1
tions compared tions t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 - 1 8 0 0 0 0 1
[21]. These [21]. [ [2 [21 [21] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 6 []. 3 9 0 0 0 0 1
advantage for advantage a ad adv adva BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 - 1 8 0 0 0 0 1
suppressive agent suppressive s su sup supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 - 1 8 0 0 0 0 1
inhibitors. inhibitors. inhibitors. i in inh inhi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 . 1 2 0 0 0 0 1
Study limitations, study S St Stu Stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 6 ,- 2 8 0 0 0 0 1
atic reviews atic a at ati atic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 , 1 8 0 0 0 0 1
overall small overall o ov ove over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 . 1 9 0 0 0 0 1
All studies all A Al All All BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 6 , 1 9 0 0 0 0 1
limiting generalizability. limiting l li lim limi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 .- 2 9 0 0 0 0 1
ber of ber b be ber ber BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 ,- 2 9 0 0 0 0 1
ate the ate a at ate ate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 10 0 0 0 0 1
of inflammatory of o of of of BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
1914 1914 1914 1 19 191 1914 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 8 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ()():- 6 10 0 1 1 0 1
failed treatments. failed f fa fai fail BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 9 0 1 0 0 1
risk of risk r ri ris risk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 10 0 1 0 0 1
series. Lastly, series. s se ser seri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 .,- 3 9 0 1 0 0 1
mens, outcome mens, m me men mens BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,, 2 8 0 1 0 0 1
efficacy measurements. efficacy e ef eff effi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 4 0 1 0 0 1
CONCLUSIONS CONCLUSIONS conclusions C CO CON CONC BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 10 0 0 0 0 1
Overall, ustekinumab overall, O Ov Ove Over BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 , 1 9 0 0 0 0 1
to consider to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
have failed have h ha hav have BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 - 1 9 0 0 0 0 1
TNF-alpha or tnf-alpha T TN TNF TNF- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 -- 2 9 0 0 0 0 1
phase III phase p ph pha phas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ,,- 3 9 0 0 0 0 1
marketing data marketing m ma mar mark BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 0 .- 2 8 0 0 0 0 1
trolled trials trolled t tr tro trol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 no 0 10 0 0 0 0 1
efficacy, safety, efficacy, e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ,, 2 9 0 0 0 0 1
ustekinumab in ustekinumab u us ust uste BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 . 1 9 0 0 0 0 1
evaluate the evaluate e ev eva eval BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
with ustekinumab with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 8 0 0 0 0 1
Studies that studies S St Stu Stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
that may that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ,- 2 9 0 0 0 0 1
vival rates, vival v vi viv viva BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 , 1 9 0 0 0 0 1
drug monitoring drug d dr dru drug BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 7 0 0 0 0 1
Author Contributions. author A Au Aut Auth BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 .: 2 6 0 0 0 0 1
drafting of drafting d dr dra draf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ,;- 3 9 0 0 0 0 1
tine Seivright: tine t ti tin tine BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 9 2 :, 2 10 0 0 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ;: 2 9 0 0 0 0 1
analyses, critical analyses, a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ,; 2 9 0 0 0 0 1
Swetha Atluri: swetha S Sw Swe Swet BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 2 :- 2 8 0 0 0 0 1
script; Iltefat script; s sc scr scri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ;: 2 9 0 0 0 0 1
manuscript; Marcia manuscript; m ma man manu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ;: 2 9 0 0 0 0 1
the manuscript; the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ;.: 3 10 0 0 0 0 1
the manuscript; the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ;.: 3 9 0 0 0 0 1
design, critical design, d de des desi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ,,- 3 9 0 0 0 0 1
vision, and vision, v vi vis visi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ,. 2 5 0 0 0 0 1
Funding. Statistical funding. F Fu Fun Fund BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 4 . 1 8 0 0 0 0 1
research was research r re res rese BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 4 no 0 10 0 0 0 0 1
for Advancing for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 () 2 9 0 0 0 0 1
UCLA CTSI ucla U UC UCL UCLA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 4 . 1 8 0 0 0 0 1
funding or funding f fu fun fund BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 no 0 9 0 0 0 0 1
study or study s st stu stud BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 . 1 8 0 0 0 0 1
Data Availability. data D Da Dat Data BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 .- 2 9 0 0 0 0 1
cable to cable c ca cab cabl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 5 no 0 10 0 0 0 0 1
or analyzed or o or or or BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 . 1 5 0 0 0 0 1
Declarations Declarations declarations D De Dec Decl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 no 0 10 0 1 0 0 1
Conflict of conflict C Co Con Conf BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 .. 2 9 0 0 0 0 1
the Board the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 - 1 9 0 0 0 0 1
purativa Foundation purativa p pu pur pura BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 - 1 9 0 0 0 0 1
ant for ant a an ant ant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 ,,, 3 9 0 0 0 0 1
and Novartis, and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 ,, 2 9 0 0 0 0 1
an investigator an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 5 ,, 2 9 0 0 0 0 1
Ingelheim, and ingelheim, I In Ing Inge BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,.. 3 9 0 0 0 0 1
editorial board editorial e ed edi edit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 - 1 9 0 0 0 0 1
apy. Jennifer apy. a ap apy apy. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 .. 2 9 0 0 0 0 1
selection of selection s se sel sele BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 no 0 9 0 0 0 0 1
nor any nor n no nor nor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 . 1 9 0 0 0 0 1
Vivian Y. vivian V Vi Viv Vivi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 5 . 1 10 0 0 0 0 1
Hidradenitis Suppurativa hidradenitis H Hi Hid Hidr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 (), 3 9 0 0 0 0 1
an advisor an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 5 , 1 9 0 0 0 0 1
is a is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 , 1 9 0 0 0 0 1
served as served s se ser serv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 ,- 2 9 0 0 0 0 1
tor, or tor, t to tor tor, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,/- 3 9 0 0 0 0 1
ing from ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 9 5 ,,, 3 8 0 0 0 0 1
Genentech, Eli genentech, G Ge Gen Gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,, 4 8 0 0 0 0 1
LEO Pharma, leo L LE LEO LEO BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 9 5 ,,,- 4 8 0 0 0 0 1
heim, Almirall, heim, h he hei heim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,, 4 9 0 0 0 0 1
Menlo Therapeutics, menlo M Me Men Menl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,',- 5 9 0 0 0 0 1
derma, Kiniksa, derma, d de der derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,,-- 6 9 0 0 0 0 1
maSolutions, Altus masolutions, m ma maS maSo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,/,, 4 9 0 0 0 0 1
Technology, GpSkin, technology, T Te Tec Tech BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 ,,- 3 8 0 0 0 0 1
tific. Iltefat tific. t ti tif tifi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 . 1 9 0 0 0 0 1
to Abbvie, to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 ,,,,- 5 9 0 0 0 0 1
heim, Sonoma, heim, h he hei heim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,, 4 8 0 0 0 0 1
Jansen, Avita, jansen, J Ja Jan Jans BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,, 3 8 0 0 0 0 1
investigator for investigator i in inv inve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 ,,,, 4 9 0 0 0 0 1
and Loreal/Laroche and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 /,- 3 8 0 0 0 0 1
ber and ber b be ber ber BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 - 1 8 0 0 0 0 1
and Global and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 . 1 8 0 0 0 0 1
financial transaction financial f fi fin fina BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 no 0 9 0 0 0 0 1
manuscript. All manuscript. m ma man manu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 . 1 9 0 0 0 0 1
of interest. of o of of of BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 . 1 2 0 0 0 0 1
Ethical Approval. ethical E Et Eth Ethi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 10 . 1 8 0 0 0 0 1
previously conducted previously p pr pre prev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 10 - 1 9 0 0 0 0 1
tain any tain t ta tai tain BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 10 no 0 9 0 0 0 0 1
or animals or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 10 . 1 10 0 0 0 0 1
databases used databases d da dat data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 10 - 1 10 0 0 0 0 1
able: MEDLINE: able: a ab abl able BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 10 ::://.... 9 10 0 0 0 0 1
gov/ and gov/ g go gov gov/ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 10 /:://../ 8 9 0 0 0 0 1
search/ quick. search/ s se sea sear BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 10 /. 2 3 0 0 0 0 1
1915 1915 1915 1 19 191 1915 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 9 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ()():- 6 10 0 1 1 0 1
Open Access. open O Op Ope Open BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 8 0 0 0 0 1
Creative Commons creative C Cr Cre Crea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 - 1 7 0 0 0 0 1
4.0 International 4.0 4 4. 4.0 4.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 ., 2 8 0 0 0 0 1
non-commercial use, non-commercial n no non non- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 -,,,- 5 8 0 0 0 0 1
bution and bution b bu but buti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 - 1 8 0 0 0 0 1
mat, as mat, m ma mat mat, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 , 1 9 0 0 0 0 1
original author(s) original o or ori orig BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 (), 3 9 0 0 0 0 1
to the to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 , 1 8 0 0 0 0 1
if changes if i if if if BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 8 0 0 0 0 1
party material party p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 9 0 0 0 0 1
article's Creative article's a ar art arti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ',- 3 8 0 0 0 0 1
cated otherwise cated c ca cat cate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
If material if I If If If BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 '- 2 9 0 0 0 0 1
tive Commons tive t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 8 0 0 0 0 1
not permitted not n no not not BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 8 0 0 0 0 1
the permitted the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,- 2 8 0 0 0 0 1
mission directly mission m mi mis miss BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 8 0 0 0 0 1
view a view v vi vie view BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,:// 4 10 0 0 0 0 1
mmons. org/ mmons. m mm mmo mmon BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 .//-/./. 8 6 0 0 0 0 1
REFERENCES REFERENCES references R RE REF REFE BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 10 2 no 0 10 0 0 0 0 1
1. Jemec 1. 1 1. 1. 1. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 2 ... 3 10 0 0 0 0 1
Med. 2012;366(2):158-64. med. M Me Med Med. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 2 .;():-.://./. 13 9 0 0 0 0 1
1056/ NEJMc 1056/ 1 10 105 1056 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 2 /. 2 4 0 0 0 0 1
2. Moltrasio 2. 2 2. 2. 2. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 2 .,,,- 5 9 0 0 0 0 1
zano AV, zano z za zan zano BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 2 ,.: 3 9 0 0 0 0 1
perspective on perspective p pe per pers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 2 - 1 10 0 0 0 0 1
ease. Biomedicines. ease. e ea eas ease BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 2 ..;():.://. 11 10 0 0 0 0 1
org/ 10. org/ o or org org/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 2 /./. 4 7 0 0 0 0 1
3. Nardacchione 3. 3 3. 3. 3. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 3 .,,,. 5 9 0 0 0 0 1
Unraveling the unraveling U Un Unr Unra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 3 : 1 9 0 0 0 0 1
impact of impact i im imp impa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 3 no 0 10 0 0 0 0 1
suppurativa pathogenesis. suppurativa s su sup supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 3 ..;():. 7 9 0 0 0 0 1
https:// doi. https:// h ht htt http BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 1 10 3 ://././. 8 9 0 0 0 0 1
4. Zouboulis 4. 4 4. 4. 4. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 3 .,,,. 5 10 0 0 0 0 1
causes hidradenitis causes c ca cau caus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 3 ?-. 3 9 0 0 0 0 1
Exp Dermatol. exp E Ex Exp Exp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 3 .;():-.://. 11 9 0 0 0 0 1
org/ 10. org/ o or org org/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 3 /./.. 5 5 0 0 0 0 1
5. Goldburg 5. 5 5. 5. 5. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 4 .,,. 4 10 0 0 0 0 1
suppurativa: current suppurativa: s su sup supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 4 :. 2 9 0 0 0 0 1
Am Acad am A Am Am Am BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 4 .;():-.:// 10 8 0 0 0 0 1
doi. org/ doi. d do doi doi. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 4 ././..... 9 8 0 0 0 0 1
6. Maronese 6. 6 6. 6. 6. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,,, 4 9 0 0 0 0 1
AV. Biologics av. A AV AV. AV. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 .:- 3 9 0 0 0 0 1
tion of tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 . 1 9 0 0 0 0 1
Immunol. 2024;20(5):525-45. immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 .;():-.://./. 13 10 0 0 0 0 1
1080/ 17446 1080/ 1 10 108 1080 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 /... 4 6 0 0 0 0 1
7. Kimball 7. 7 7. 7. 7. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,,,. 5 10 0 1 0 0 1
phase 3 phase p ph pha phas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 9 0 1 0 0 1
suppurativa. N suppurativa. s su sup supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 ..;():-. 8 9 0 1 0 0 1
https:// doi. https:// h ht htt http BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 1 10 5 ://././. 8 9 0 1 0 0 1
8. Montero-Vilchez 8. 8 8. 8. 8. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .-,-,-- 7 9 0 0 0 0 1
cia L, cia c ci cia cia BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 ,-,-,- 6 9 0 0 0 0 1
Leyva A. leyva L Le Ley Leyv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 10 6 . 1 9 0 0 0 0 1
with hidradenitis with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 : 1 8 0 0 0 0 1
series and series s se ser seri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 .. 2 8 0 0 0 0 1
2022;33(1):348-53. https:// 2022;33(1):348-53. 2 20 202 2022 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 6 ;():-.://././ 13 10 0 0 0 0 1
634. 2020. 634. 6 63 634 634. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 ... 3 3 0 0 0 0 1
9. Blok 9. 9 9. 9. 9. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 7 .,,,,- 6 9 0 0 0 0 1
man MF, man m ma man man BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 7 ,.- 3 8 0 0 0 0 1
tis suppurativa: tis t ti tis tis BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 7 : 1 9 0 0 0 0 1
potential biomarkers potential p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 .. 2 8 0 0 0 0 1
2016;174(4):839-46. https:// 2016;174(4):839-46. 2 20 201 2016 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 7 ;():-.://././. 14 10 0 0 0 0 1
14338. 14338. 14338. 1 14 143 1433 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 7 . 1 1 0 0 0 0 1
10. Hollywood 10. 1 10 10. 10. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 7 .,,,, 5 9 0 0 0 0 1
Hughes R. hughes H Hu Hug Hugh BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 10 7 . 1 8 0 0 0 0 1
hidradenitis suppurativa: hidradenitis h hi hid hidr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 7 :. 2 10 0 0 0 0 1
Drugs Dermatol. drugs D Dr Dru Drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 7 .;():-.://. 11 9 0 0 0 0 1
org/ 10. org/ o or org org/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 7 /./.. 5 5 0 0 0 0 1
11. Jiang 11. 1 11 11. 11. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .,,,.-,- 8 10 0 0 0 0 1
frequency ustekinumab frequency f fr fre freq BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 no 0 8 0 0 0 0 1
severe hidradenitis severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 .. 2 8 0 0 0 0 1
2022;187(3):417-9. https:// 2022;187(3):417-9. 2 20 202 2022 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 8 ;():-.://././. 14 9 0 0 0 0 1
21066. 21066. 21066. 2 21 210 2106 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 8 . 1 1 0 0 0 0 1
12. Schlapbach 12. 1 12 12. 12. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 .,,,. 5 9 0 0 0 0 1
Expression of expression E Ex Exp Expr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 9 -/ 2 8 0 0 0 0 1
of hidradenitis of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 9 .. 2 8 0 0 0 0 1
2011;65(4):790-8. https:// 2011;65(4):790-8. 2 20 201 2011 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 9 ;():-.://././.. 15 10 0 0 0 0 1
2010. 07. 2010. 2 20 201 2010 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 9 ... 3 2 0 0 0 0 1
13. Meserve 13. 1 13 13. 13. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 .,,,,. 6 10 0 0 0 0 1
Effectiveness of effectiveness E Ef Eff Effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 9 /- 2 9 0 0 0 0 1
tion of tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 9 ':- 3 9 0 0 0 0 1
atic review atic a at ati atic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 9 -. 2 9 0 0 0 0 1
Hepatol. 2021;20:2728-2740.e1. hepatol. H He Hep Hepa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 9 .;:-..://./ 11 9 0 0 0 0 1
10. 1016/j. 10. 1 10 10. 10. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 ./.....( 8 9 0 0 0 0 1
October 8). october O Oc Oct Octo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 1 0 0 10 9 ). 2 2 0 0 0 0 1
14. Brezinski 14. 1 14 14. 14. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 10 .,.- 4 9 0 0 0 0 1
regimens in regimens r re reg regi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 10 :- 2 9 0 0 0 0 1
cacy and cacy c ca cac cacy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 10 ,, 2 9 0 0 0 0 1
interrupted biologic interrupted i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 10 ..;(): 6 9 0 0 0 0 1
e33486. https:// e33486. e e3 e33 e334 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 10 .://././.. 10 10 0 0 0 0 1
00334 86. 00334 0 00 003 0033 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 10 . 1 1 0 0 0 0 1
15. Nazzaro 15. 1 15 15. 15. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 .,,,.- 6 10 0 0 0 0 1
tion and tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 11 no 0 8 0 0 0 0 1
tools for tools t to too tool BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 11 11 no 0 8 0 0 0 0 1
hidradenitis suppurativa: hidradenitis h hi hid hidr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 11 : 1 8 0 0 0 0 1
32 patients. 32 3 32 32 32 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 11 11 ..;():. 7 8 0 0 0 0 1
https:// doi. https:// h ht htt http BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 1 11 11 ://././.. 9 7 0 0 0 0 1
1916 1916 1916 1 19 191 1916 BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 11 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 ()():- 6 10 0 1 1 0 1
16. Rowan 16. 1 16 16. 16. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,,,. 5 10 0 1 0 0 1
rather than rather r ra rat rath BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 no 0 9 0 1 0 0 1
associated with associated a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 no 0 9 0 1 0 0 1
and early and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 :. 2 9 0 1 0 0 1
Pharmacol Ther. pharmacol P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 .;():-.://. 11 9 0 1 0 0 1
org/ 10. org/ o or org org/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 0 /./.. 5 5 0 1 0 0 1
17. Tsakok 17. 1 17 17. 17. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 1 .,,,. 5 9 0 0 0 0 1
serum ustekinumab serum s se ser seru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 1 no 0 8 0 0 0 0 1
in psoriasis. in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 11 1 ..;():. 7 8 0 0 0 0 1
https:// doi. https:// h ht htt http BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 1 11 1 ://././... 10 10 0 0 0 0 1
18. Hsu 18. 1 18 18. 18. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 2 .,,. 4 9 0 0 0 0 1
antibodies in antibodies a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 2 :. 2 9 0 0 0 0 1
Dermatol. 2014;170(2):261-73. dermatol. D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 2 .;():-.://./. 13 10 0 0 0 0 1
1111/ bjd. 1111/ 1 11 111 1111 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 2 /.. 3 3 0 0 0 0 1
19. Ring 19. 1 19 19. 19. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 2 .,,,.- 6 10 0 0 0 0 1
logics in logics l lo log logi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 2 . 1 8 0 0 0 0 1
JAMA Dermatol. jama J JA JAM JAMA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 11 2 .;():-.://. 11 8 0 0 0 0 1
org/ 10. org/ o or org org/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 2 /./... 6 7 0 0 0 0 1
20. Sandborn 20. 2 20 20. 20. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 3 .,,,. 5 10 0 0 0 0 1
of ustekinumab of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 : 1 8 0 0 0 0 1
pooled safety pooled p po poo pool BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 / 1 9 0 0 0 0 1
studies. Inflamm studies. s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 ..;():-. 8 9 0 0 0 0 1
https:// doi. https:// h ht htt http BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 1 11 3 ://././/. 9 8 0 0 0 0 1
21. Cheng 21. 2 21 21. 21. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 4 .,,, 4 9 0 0 0 0 1
AN. Risk an. A AN AN. AN. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 11 4 . 1 8 0 0 0 0 1
tofacitinib compared tofacitinib t to tof tofa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 4 no 0 9 0 0 0 0 1
antagonists in antagonists a an ant anta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 4 . 1 9 0 0 0 0 1
Gastroenterol Hepatol. gastroenterol G Ga Gas Gast BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 4 .;():-.. 8 9 0 0 0 0 1
https:// doi. https:// h ht htt http BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 1 11 4 ://././..... 12 10 0 0 0 0 1
22. Romaní 22. 2 22 22. 22. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,, 5 10 0 0 0 0 1
Ciudad C, ciudad C Ci Ciu Ciud BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 6 ,-. 3 8 0 0 0 0 1
intravenous infusion: intravenous i in int intr BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 :- 2 10 0 1 0 0 1
purativa. Dermatology. purativa. p pu pur pura BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 ..;():-.:// 11 10 0 1 0 0 1
doi. org/ doi. d do doi doi. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 ././. 5 6 0 1 0 0 1
23. Valenzuela-Ubiña 23. 2 23 23. 23. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 7 .-,-,- 6 9 0 0 0 0 1
Romero I, romero R Ro Rom Rome BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 11 7 ,-,- 4 8 0 0 0 0 1
M. Effectiveness m. M M. M. M. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 7 .- 2 8 0 0 0 0 1
to-severe hidradenitis to-severe t to to- to-s BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 7 -:. 3 10 0 0 0 0 1
Dermatol Treat. dermatol D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 7 .;():-.://. 11 9 0 0 0 0 1
org/ 10. org/ o or org org/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 7 /./... 6 7 0 0 0 0 1
24. Sánchez-Martínez 24. 2 24 24. 24. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 8 .-,-,- 6 8 0 0 0 0 1
Léniz LM, léniz L Lé Lén Léni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 8 ,-. 3 8 0 0 0 0 1
safety of safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 8 - 1 8 0 0 0 0 1
enitis suppurativa enitis e en eni enit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 8 . 1 8 0 0 0 0 1
Dermatol Ther. dermatol D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 8 ..://././. 10 10 0 0 0 0 1
14054. 14054. 14054. 1 14 140 1405 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 8 . 1 1 0 0 0 0 1
25. Gulliver 25. 2 25 25. 25. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 9 .,,. 4 9 0 0 0 0 1
with ustekinumab with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 no 0 8 0 0 0 0 1
to severe to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 .- 2 9 0 0 0 0 1
matol Venereol. matol m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 9 .;():-.://./ 12 10 0 0 0 0 1
10. 1111/j. 10. 1 10 10. 10. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 9 ./.-.... 8 7 0 0 0 0 1
26. Martin-Ezquerra 26. 2 26 26. 26. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .-,,- 5 9 0 0 0 0 1
M, et m, M M, M, M, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 10 ,. 2 9 0 0 0 0 1
with hidradenitis with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 10 .- 2 8 0 0 0 0 1
tol Venereol. tol t to tol tol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 .;():-.://./. 13 10 0 0 0 0 1
1111/ jdv. 1111/ 1 11 111 1111 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 10 /.. 3 3 0 0 0 0 1
27. Scholl 27. 2 27 27. 27. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 .,,,. 5 9 0 0 0 0 1
High-dosage ustekinumab high-dosage H Hi Hig High BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 - 1 8 0 0 0 0 1
severe hidradenitis severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 11 .. 2 9 0 0 0 0 1
2019;29(6):659-61. https:// 2019;29(6):659-61. 2 20 201 2019 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 11 ;():-.://././. 14 10 0 0 0 0 1
2019. 3663. 2019. 2 20 201 2019 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 11 .. 2 2 0 0 0 0 1

